Form 4: Solid Biosciences Officer Sells Shares for Tax Cover

Solid Biosciences Chief Regulatory Officer Jessie Hanrahan sold 4,483 shares of common stock at $5.11 per share to cover tax obligations following RSU vesting.

Summary

• Jessie Hanrahan, Chief Regulatory Officer of Solid Biosciences Inc., reported transactions involving the company's common stock and Restricted Stock Units (RSUs).
• On December 2, 2025, 11,862 RSUs vested, converting into 11,862 shares of common stock.
• Following this vesting, on December 3, 2025, Hanrahan sold 4,483 shares of common stock at a price of $5.11 per share.
• This sale was a non-discretionary "sell-to-cover" transaction, executed to satisfy tax withholding obligations related to the RSU vesting, as per a pre-arranged plan adopted on August 16, 2024.
• After these transactions, Hanrahan beneficially owns 26,660 shares of common stock and 11,863 Restricted Stock Units.

Sentiment

Score: 5

Explanation: The transaction is neutral. It's a routine, non-discretionary 'sell-to-cover' for tax purposes following RSU vesting, which is a common event for executives and does not indicate a change in management's confidence or the company's prospects.

Positives

• The sale was non-discretionary, indicating it was for tax purposes rather than a lack of confidence in the company.
• The vesting of RSUs represents a compensation event for the officer.

Negatives

• A reduction in direct share ownership by a key officer, even if for tax purposes.

Risks

• No specific risks to the company's operations or financial health are mentioned. The routine nature of insider selling for tax purposes can sometimes be misinterpreted by the market.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale does not represent a discretionary trade by Dr. Hanrahan.

Industry Context

This routine insider transaction, a 'sell-to-cover' for tax obligations, is common across all industries for executives receiving equity compensation. It does not reflect specific industry trends or competitive positioning for Solid Biosciences.

Comparison to Industry Standards

• The transaction is a standard 'sell-to-cover' event, a common practice for executives across publicly traded companies when equity awards vest.
• This type of transaction is widely accepted as a non-discretionary event and is not typically compared to specific company or project results, but rather to general corporate governance and compensation practices.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting, but the sell-to-cover is a routine event and generally not seen as a negative signal.
• Employees: The RSU vesting and subsequent tax-related sale are part of standard executive compensation practices.

Next Steps

• Continued vesting of the remaining 11,863 Restricted Stock Units on future anniversaries of the December 2, 2022 grant date.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary 'sell-to-cover' transaction by a Chief Regulatory Officer to satisfy tax obligations upon RSU vesting. Such transactions are common and do not typically signal a change in the company's fundamentals or management's outlook. Therefore, it provides no new information to warrant a change in investment recommendation, maintaining a 'hold' stance based solely on this filing.

Keywords

Solid Biosciences, SLDB, Jessie Hanrahan, Chief Regulatory Officer, Form 4, Insider Trading, Restricted Stock Units, RSU vesting, Sell-to-cover, Equity compensation, Stock sale